Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Becton Dickinson And Co Reaffirms FY 2013 Guidance


Thursday, 1 Aug 2013 06:01am EDT 

Becton Dickinson And Co reaffirmed its previously communicated guidance for fiscal 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to approach 5.0%, which is the upper end of the Company's previously communicated guidance range. Reported revenue growth is expected to be between 3.5% to 4.0%. Earnings per share from continuing operations for fiscal 2013 are expected to be between $5.65 and $5.68, or $5.72 and $5.75 after adjusting for a pending antitrust class action settlement. This represents growth of 6.5% to 7.0% over 2012 adjusted diluted earnings per share of $5.37, which excludes a pension settlement charge, in fiscal year 2012. On a currency-neutral basis, adjusted earnings per share growth is expected to be between 8.5 to 9.0%. After adjusting for the impact of the medical device excise tax and foreign currency, adjusted diluted earnings per share are expected to grow at the upper end of the Company's previously communicated guidance range of 11.0% to 11.5%. In line with previously disclosed guidance, the Company plans to repurchase, subject to market conditions, up to $500 million of its common stock in fiscal year 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.99 billion and EPS of $5.74 for fiscal 2013. 

Company Quote

125.73
0.73 +0.58%
24 Oct 2014